Devensoft

AUGUST 22, 2023

Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Cooley M&A

FEBRUARY 8, 2018

What’s on tap for 2018 M&A? As an example, for California specific requirements, see our prior blog post Non-Competes for California Employees in M&A Deals: Don’t Fudge It. A recap of 2017 trends and the Cooley outlook on this year’s dealmaking: Buying Innovation: Retention and Non-Competes.

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

Cooley M&A

JANUARY 22, 2020

2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 40

M&A Pharmaceutical Acquisitions Valuation 40

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JULY 10, 2017

Similarly, sellers (particularly financial investors) in private M&A transactions are increasingly seeking the right to be able to monetize their rights to contingent consideration by requesting royalty-like earn-out streams and requesting a right to sell the potential future payments to a single third-party purchaser. Private placement.

Securities 52

Securities IT Investors M&A 52

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Global Newswire by Notified: M&A

JANUARY 12, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Global Newswire by Notified: M&A

JANUARY 9, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Global Newswire by Notified: M&A

JANUARY 3, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Global Newswire by Notified: M&A

JANUARY 16, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 15, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 11, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 8, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 5, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 4, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 2, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 29, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 27, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

How2Exit

OCTOBER 2, 2023

Their team is experienced in M&A, and they hire the best talent available. rn About The Guest(s): Corey Veverka is the owner of TBS, a company that specializes in validation and compliance for pharmaceutical manufacturing facilities. Reconciled sets the standard for consistency and quality that you can count on.

Business 130

Business Finance Finance Recruitment 130

Global Newswire by Notified: M&A

DECEMBER 22, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 21, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 20, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 19, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 18, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 15, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 14, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 13, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 12, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 11, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 8, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 7, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 6, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 5, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 4, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 1, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 29, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40